
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ecopipam
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Food-effect Study of Ecopipam Pharmacokinetics
Details : Ecopipam is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 01, 2024
Lead Product(s) : Ecopipam
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Itraconazole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Syneos Health | Cambridge Cognition
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Itraconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 08, 2024
Lead Product(s) : Itraconazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Syneos Health | Cambridge Cognition
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : Ecopipam Hydrochloride, a novel investigational compound that is being studied as a potential treatment for Tourette Syndrome, by blocking the action of the neurotransmitter dopamine at the D1 receptor.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 05, 2023

Details : Ecopipam is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tourette Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 01, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ecopipam HCl
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : PPD | Bioclinica
Deal Size : Inapplicable
Deal Type : Inapplicable
Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization
Details : Ecopipam HCl is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Long QT Syndrome.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 03, 2023
Lead Product(s) : Ecopipam HCl
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : PPD | Bioclinica
Deal Size : Inapplicable
Deal Type : Inapplicable

Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome
Details : Ecopipam hydrochloride is a first-in-class dopamine-1 receptor antagonist which blocks the actions of the neurotransmitter dopamine at the D1 receptor. It is currently approved to treat tourette syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 01, 2023

Emalex Biosciences Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics
Details : Ecopipam Hydrochloride, a novel investigational compound that is being studied as a potential treatment for certain central nervous system disorders, by blocking the action of the neurotransmitter dopamine at the D1 receptor.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 11, 2023

Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults
Details : Ecopipam HCl is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tourette Syndrome.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 14, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ecopipam
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Icon Plc | Nuventra
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ecopipam is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 19, 2022
Lead Product(s) : Ecopipam
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Icon Plc | Nuventra
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ecopipam
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : University of California
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study is evaluating ecopipam, an investigational first-in-class drug, to determine whether it may help improve the ability to get words out without stuttering.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 14, 2021
Lead Product(s) : Ecopipam
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : University of California
Deal Size : Inapplicable
Deal Type : Inapplicable
